Phyrago (Dasatinib) for Myeloproliferative Neoplasms

Overview
Phyrago is approved by the U.S. Food and Drug Administration (FDA) to treat chronic myeloid leukemia (CML), a type of blood cancer that belongs to a group called myeloproliferative neoplasms (MPNs). Phyrago is prescribed for adults with CML who have a specific genetic feature called the Philadelphia chromosome (Ph+). It’s given to those who are newly diagnosed, as well as to those who haven’t responded well to other treatments. Phyrago’s drug name is dasatinib.

Dasatinib works by blocking certain proteins that help cancer cells grow and survive. By stopping these proteins, Phyrago helps lower the number of abnormal blood cells, which can improve symptoms and slow down the disease.

How do I take it?
Phyrago is taken as a tablet by mouth. For people with chronic phase CML, the typical dose is once a day. For advanced phases of CML, a higher dose may be given daily. Phyrago can be taken with or without food, but the tablets shouldn’t be crushed, cut, or chewed. Take it exactly as your health care provider prescribes.

Side effects
Common side effects of Phyrago include low blood cell counts, fluid retention, diarrhea, headache, skin rash, bleeding, shortness of breath, tiredness, nausea, and muscle or bone pain.

Rare but serious side effects can include very low blood cell counts (sometimes requiring transfusions or a break from treatment), fluid buildup around the lungs, heart problems, high blood pressure in the lungs, irregular heartbeats, severe skin reactions, rapid breakdown of cancer cells, risk to an unborn baby, and liver damage. In children, it may also affect bone growth, cause low bone density, or lead to enlarged breast tissue in males.

For more information about this treatment, visit:

Label: Phyrago — Dasatinib Tablet — DailyMed